PDL BioPharma, Inc. (PDLI)
| Market Cap | 282.14M |
| Revenue (ttm) | 13.44M |
| Net Income (ttm) | -154.37M |
| Shares Out | 115.91M |
| EPS (ttm) | -1.32 |
| PE Ratio | n/a |
| Forward PE | 64.94 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | December 30 |
| Last Price | $2.47 |
| Previous Close | $2.47 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 2.47 - 2.47 |
| Day's Volume | 0 |
| 52-Week Range | 0.00 - 2.47 |
RENO, Nev., Dec. 14, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces it has entered into a Capital Provision Agreement (the "Agreement") with Epps In...
PDLI is liquidating, it should delist from the NASDAQ on December 31, 2020. Patient investors can ultimately expect a return of approximately 40% based on net assets.
PDL BioPharma's (PDLI) CEO Dominique Monnet on Q3 2020 Results - Earnings Call Transcript
Shares of PDL BioPharma (NASDAQ:PDLI) rose 7.96% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 211.11% year over year to ($0.10)...
INCLINE VILLAGE, Nev., Nov. 11, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and nine months ended September 30, 202...
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment o...
INCLINE VILLAGE, Nev., Nov. 6, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces it has rescheduled the date for announcing third quarter 2020 financia...
PDL BioPharma has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment o...
INCLINE VILLAGE, Nev., Sept. 9, 2020 /PRNewswire/ -- PDL BioPharma, Inc.
PDL BioPharma Announces Sale of Kybella®, Zalviso® and Coflex® Royalties to SWK Holdings Corporation
INCLINE VILLAGE, Nev., Aug. 31, 2020 /PRNewswire/ -- PDL BioPharma, Inc.
INCLINE VILLAGE, Nev., Aug. 28, 2020 /PRNewswire/ -- PDL BioPharma, Inc.
PDL BioPharma, Inc. (PDLI) CEO Dominique Monnet on Q2 2020 Results - Earnings Call Transcript
INCLINE VILLAGE, Nev., Aug. 6, 2020 /PRNewswire/ -- PDL BioPharma, Inc.
INCLINE VILLAGE, Nev., July 30, 2020 /PRNewswire/ -- PDL BioPharma, Inc.
PDL BioPharma's (PDLI) CEO Dominique Monnet on Q1 2020 Results - Earnings Call Transcript
PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock?
PDL BioPharma's (PDLI) earnings lag estimates in the fourth quarter. The company announces plan to complete liquidation by the end of 2020.
PDL BioPharma, Inc. (PDLI) CEO Dominique Monnet on Q4 2019 Results - Earnings Call Transcript
The company announced the completion of a strategic review with plans that could mean good news for investors.
PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock?
PDL BioPharma (PDLI) impresses investors with third-quarter earnings beat. LENSAR laser system bumps up sales as well.
PDL BioPharma's (PDLI) CEO Dominique Monnet on Q3 2019 Results - Earnings Call Transcript
A letter from an activist investor to the company's board of directors is lighting a fire beneath this healthcare stock.
PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock?
Tracking weekly changes in fundamental and price trend for 5,200 companies.
PDL BioPharma's (PDLI) earnings exceed estimates in the second quarter of 2019. However, the company generates negative revenues due to a change in the fair value of royalty rights.
PDL BioPharma's (PDLI) CEO Dominique Monnet on Q2 2019 Results - Earnings Call Transcript
PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock?
PDL BioPharma (PDLI) aims to acquire and manage high-yielding assets and maximize shareholder value. Blindly falling back on partners for royalties is a persistent concern.
PDL BioPharma's (PDLI) earnings exceed estimates in the first quarter of 2019. Higher royalty rights as well as product sales lead to a marginal spurt in year-over-year revenues
PDL BioPharma, Inc. (PDLI) CEO Dominique Monnet on Q1 2019 Results - Earnings Call Transcript
During PDL BioPharma's (PDLI) Q1 conference call, investor focus will be on the company's ability to acquire new income-generating assets for frequent revenue growth.
Evofem's lead drug (Amphora) passed Phase 3 clinical trials. Amphora is a differentiated contraception drug. PDL will make an investment in Evofem up to 29% of equity.
PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock?
Does PDL BioPharma (PDLI) have what it takes to be a top stock pick for momentum investors? Let's find out.
PDL BioPharma is reaching a technical resistance point.
PDL BioPharma Inc.'s (PDLI) CEO Dominique Monnet on Q4 2018 Results - Earnings Call Transcript
About PDLI
PDL BioPharma manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
| Industry Biotechnology | IPO Date Jan 28, 1992 |
| CEO John McLaughlin | Employees 109 |
| Stock Exchange NASDAQ | Ticker Symbol PDLI |
Financial Performance
In 2019, PDL BioPharma's revenue was $54.76 million, a decrease of -72.36% compared to the previous year's $198.11 million. Losses were -$70.41 million, 2.25% more than in 2018.
Analyst Forecasts
The average 12-month stock price forecast for PDL BioPharma is 2.50, which is an increase of 1.21% from the latest price.